Profund Advisors LLC decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 11.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,489 shares of the company’s stock after selling 2,816 shares during the period. Profund Advisors LLC’s holdings in Neurocrine Biosciences were worth $1,899,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Evolution Wealth Advisors LLC bought a new position in shares of Neurocrine Biosciences in the 2nd quarter worth approximately $40,000. Capital Investment Advisory Services LLC bought a new position in shares of Neurocrine Biosciences in the 2nd quarter worth approximately $43,000. NEXT Financial Group Inc raised its position in shares of Neurocrine Biosciences by 89.8% in the 2nd quarter. NEXT Financial Group Inc now owns 560 shares of the company’s stock worth $47,000 after acquiring an additional 265 shares in the last quarter. Clarus Wealth Advisors raised its position in shares of Neurocrine Biosciences by 313.4% in the 2nd quarter. Clarus Wealth Advisors now owns 802 shares of the company’s stock worth $68,000 after acquiring an additional 608 shares in the last quarter. Finally, Golden State Wealth Management LLC raised its position in shares of Neurocrine Biosciences by 100.0% in the 2nd quarter. Golden State Wealth Management LLC now owns 1,000 shares of the company’s stock worth $84,000 after acquiring an additional 500 shares in the last quarter. 96.23% of the stock is owned by institutional investors and hedge funds.
NBIX stock traded up $2.28 on Friday, reaching $96.41. 664,065 shares of the company traded hands, compared to its average volume of 576,574. Neurocrine Biosciences, Inc. has a one year low of $64.72 and a one year high of $125.59. The company has a debt-to-equity ratio of 0.96, a current ratio of 7.44 and a quick ratio of 7.32. The company has a market cap of $8.74 billion, a P/E ratio of 438.23, a price-to-earnings-growth ratio of 5.88 and a beta of 1.26. The firm has a fifty day simple moving average of $95.90 and a 200-day simple moving average of $86.09.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Monday, July 29th. The company reported $0.37 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.13. Neurocrine Biosciences had a return on equity of 0.46% and a net margin of 2.98%. The company had revenue of $183.58 million during the quarter, compared to analyst estimates of $161.79 million. During the same quarter last year, the company earned ($0.07) EPS. The firm’s revenue for the quarter was up 89.5% on a year-over-year basis. On average, sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 0.68 EPS for the current year.
In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 7,220 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $87.63, for a total transaction of $632,688.60. Following the sale, the insider now directly owns 149,096 shares in the company, valued at approximately $13,065,282.48. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Eric Benevich sold 5,835 shares of the stock in a transaction on Monday, July 15th. The shares were sold at an average price of $87.44, for a total value of $510,212.40. Following the sale, the insider now owns 14,910 shares in the company, valued at $1,303,730.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 183,561 shares of company stock valued at $17,342,228. 4.30% of the stock is owned by corporate insiders.
Several brokerages have recently issued reports on NBIX. Guggenheim began coverage on Neurocrine Biosciences in a research report on Tuesday, June 4th. They issued a “neutral” rating and a $88.00 target price for the company. CIBC began coverage on Neurocrine Biosciences in a research report on Tuesday, July 16th. They issued an “outperform” rating and a $100.00 target price for the company. BidaskClub lowered Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Friday. ValuEngine raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, July 31st. Finally, Oppenheimer began coverage on Neurocrine Biosciences in a research report on Tuesday, July 16th. They issued an “outperform” rating and a $100.00 target price for the company. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $106.05.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
See Also: Hedge Funds – Risk or Reward?
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.